The class A Klebsiella pneumoniae carbapenemases (KPC) ß-lactamases have been extensively reported in Klebsiella pneumoniae (1) . KPC are present in more than 100 different K. pneumoniae sequence types (STs), but the KPC pandemic is primarily driven by the spread of members of clonal complex (CC) 258 namely sequence types (STs) 258 (clades I, II), ST11, ST340 and ST512 (1) .
Several different KPC-containing plasmids (i.e. IncF, IncI2, IncX, IncA/C, IncR, and ColE1) have been identified in CC258 (2) , however, the most predominant plasmid type is IncF with FIIk replicons i.e. IncFII K1 (FIB pKPN-like ) and IncFII K2 (FIB pKPQIL-like ) (3) . pKpQIL was the prototype of the IncFII K2 group and one of the most common bla KPC -harboring plasmids, reported in Israel, USA, UK, Colombia and Italy (2) . pKPN-3 was the prototype of the IncFII K1 and was not initially associated with bla KPC but was as a virulence plasmid and co-resident with pKpQIL within ST258 (2) . In the current study, we set out to determine the presence and global distribution of CC258 among a defined population consisting of 522 KPC-producing K.
pneumoniae from the AstraZeneca's (AZ) international surveillance study on antimicrobial resistance . We also investigated the association of IncFII K2-like plasmids containing bla KPC with CC258 strains in comparison to non-CC258 strains.
The AstraZeneca global surveillance program was initiated in 2012 and includes a wide representation of microbiology laboratories among the various continents (4). Up to 100 consecutive non-selected Gram-negative aerobic and facultative bacilli from each of participating countries/hospital were included. All organisms were deemed clinically significant based upon the criteria of the local investigators and were obtained from the urinary tract, skin structures, intra-abdominal, and lower respiratory tract specimens. The countries that participated in the surveillance include the following: Africa: Egypt, Kenya, Nigeria, South Africa. Asia: The AstraZeneca surveillance program does have some drawbacks; it only includes 100 consecutive non-selected Gram-negative aerobic and facultative bacilli from each of participating countries/hospital/year. It is therefore possible that the program will miss outbreaks of a particular resistance mechanism. The program is also biased towards sites that have AstraZeneca representation within that region/city/country (i.e. hospitals that can afford AstraZeneca products). Moreover, it only includes isolates from urinary tract, skin structures, intra-abdominal, and lower respiratory tract specimens. However, the program does have some significant advantages; it includes a wide representation of microbiology laboratories among the various continents, although Africa and Asia are underrepresented. It only includes clinically significant bacteria and is not biased towards a certain resistance phenotype. Therefore, it provides a "snapshot" view on what types of resistance determinants are endemic in the specific hospital/region. Molecular screening for bla KPC was performed on carbapenem resistant K. pneumoniae as described previously (5) . Genetic relatedness between the isolates was initially determined using pulsed-field gel electrophoresis (PFGE) (6) and the major pulsotypes (i.e. those with more than 10 isolates pre pulsotype) also underwent multilocus sequencing typing (MLST) (7). PCR typing was used to determine the presence of bla KPCs on IncFII K2-like types of plasmids and to also identify the different Tn4401 isotypes (8, 9) . Table 1 illustrates the PCR primers and their and 54% of KPC-3 were harboured on IncFII K2-like plasmids (Table 2) .
ST11, which is closely related to ST258, is the major ST among K. pneumoniae harboring bla KPC from Asia (especially China) (12), Latin America (13) and sometimes contain other carbapenemases (14, 15) . ST11 was the second most common ST in our study (n=80
[15%]), and was associated with bla KPC-2 on IncFII K2-like plasmids. ST11 was present in Brazil and China and to a lesser extend in Argentina, Colombia, Israel, Taiwan, USA, and Venezuela (Table 2 ).
Other STs that belong to CC258 with bla KPC have been reported from Colombia (i.e. ST512), Italy (i.e. ST512), Israel (i.e. ST512), Brazil (i.e. ST340, ST437) and Greece (i.e. ST340) (13) . The remaining members of CC258 from our study included ST512 and ST437.
ST512, mainly from Colombia, was the fourth most common ST (n=15 [3%]) in our collection
and was also identified in Israel, Italy and the USA ( Table 2 ). The ST was associated with bla KPC-3 on IncFII K2-like plasmids. ST437 (n=7) was identified in Brazil and did not contain IncF plasmids.
K. pneumoniae ST147 is an emerging high risk clone that was first identified in Greece and has been associated with bla VIM and bla KPC in that country (16) . NDM (18) and OXA-181 (6) carbapenemases have also been described in ST147 from various countries, such as Switzerland, Iraq, Canada, UK, India and Italy (1). ST147, mainly from Greece, was the third most common ST (n=27 [5%]) in our study and was associated with bla KPC-2 on IncFII K2-like plasmids. ST147 was also present in Argentina, Italy, Philippines, Romania and Venezuela (Table 2 ).
The geographical distribution of the other minor STs was as follows: ST189 (n=9) in Colombia and ST15 (n=7) in Portugal ( (Table 2) . K.
pneumoniae ST147 was also associated with IncF plasmids, especially IncFII K2-like (Table 2 ).
Our data suggests that certain successful high-risk K. pneumoniae clones (i.e. CC258 and ST147) are linked to specific narrow host range IncF plasmids with bla KPC , and this association may possess epidemiological advantages over other clones that carry non-IncF KPC plasmids. It is possible that the maintenance and co-evolution of GC258 with IncF K2-like plasmids have provided rapid and continual adaptation opportunities for this CC providing them with the additional ability to outcompete other K. pneumoniae clones. This scenario is consistent with both the macro-and micro-evolutionary versions of the Red Queen hypothesis of co-evolution (11).
However, this might be a very simplistic view regarding the role of IncF K2-like plasmids in the success of CC258 and this CC frequently harbors non-F antimicrobial resistance plasmids (1).
This study was not designed to specifically address the epidemiological advantage attributed to IncFII K2-like plasmids as compared to other features of CC258. The IncFII K2-like plasmids are clearly the most common KPC containing plasmids disseminating in K.
pneumoniae but are not necessarily restricted to CC258 (i.e. 23% of non-CC258 STs also contained IncFII K2-like plasmids). To the best of our knowledge, this is the first study that provided a comprehensive overview on the global distribution of different STs with bla KPC, and their association with IncFII K2-like plasmids in a defined population.
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